The authors concluded that there were no significant differences between low-dose aspirin and control for any pregnancy-related outcomes in women undergoing assisted reproductive technology treatment; treatment with low-dose aspirin cannot, therefore, be routinely recommended. The evidence appears to support the authors' conclusions, but poor reporting of study quality along with other review limitations make it difficult to assess the strength of the evidence.
Searching
MEDLINE, EMBASE, the Cochrane Controlled Trials Register and the UK National Research Register were searched from 1980 to March 2006; the search terms were reported. No language restrictions were applied. In addition, references and relevant conference proceedings were screened, other reports published by key authors in the field were traced, and journals containing the highest number of relevant reports were handsearched.
Study selection
Studies of any design that evaluated the effects of low-dose aspirin (150 mg or less given once daily), alone or combined with heparin or glucocorticoids, on the outcome for women undergoing IVF or ICSI were eligible for inclusion.
In the included studies, 75 to 100 mg/day aspirin was started at different stages of the treatment cycle and continued for varying durations. Some studies were in unselected patients and others were in selected IVF populations (the selection criteria varied). The review outcomes included pregnancy rate per embryo transfer (ET), clinical pregnancy rate per cycle or ET, clinical pregnancy rate per elective single ET, spontaneous abortion or ectopic pregnancy rate per clinical pregnancy, live birth rate per cycle or ET, implantation rate and cycle cancellation rate. Control groups received placebo or no treatment; in one study the controls received prednisone. Two reviewers independently selected the studies and resolved any disagreements by consensus.
Assessment of study quality
Study quality was assessed by examining the method of randomisation, allocation concealment, blinding, cointerventions, estimation of sample size, completeness of follow-up and differentiation between patients and cycles.
The authors did not state how the validity assessment was performed.
Data extraction
The number of outcome events in the intervention and comparator groups were extracted and relative risks (RRs) with 95% confidence intervals (CIs) calculated.
Two reviewers independently extracted the data and resolved any disagreements by consensus.
Methods of synthesis
Meta-analyses examining pooled RRs were performed using a random-effects model. There were insufficient studies to assess the potential for publication bias using funnel plots.
